BIO Asia–Taiwan 2025 亞洲生技大會

Join us as we spotlight the latest breakthroughs in antibody-drug conjugates (ADCs)—a driving force behind the next generation of targeted cancer therapies. This dynamic session brings together global leaders in R&D and regulatory science to explore cutting-edge innovations in ADC engineering, analytical strategies, and regulatory pathways.

 

Teiji Wada, Head of Research Platform at Daiichi Sankyo, will share insights from one of the world’s most recognized pioneers in ADC development. Yu-Hsun Lo, Director at the Institute of Biologics, Development Center for Biotechnology(DCB), will present a novel pH-dependent ADC platform engineered to enhance tumor specificity and therapeutic efficacy. Luke BI, Executive Director at Labcorp, will provide regulatory and scientific perspectives on bioanalysis strategies critical to ADC development. The session will be moderated by Tsai-Kun Li, Vice President of the DCB, and will conclude with a panel discussion featuring Edward Y. H. Hsieh, R&D VP at Formosa Laboratories.

 

Don’t miss this opportunity to explore the science, strategy, and regulation behind one of the most dynamic fields in oncology.